Advertisement

Advertisement

prostate cancer

Prostate Cancer Imaging: Ultrasound, CT, MRI, and Nuclear Medicine Techniques

Teaser: 

D'Arcy Little MD CCFP FCFP FRCPC,

Radiologist, Orillia Soldiers' Memorial Hospital, Adjunct Clinical Lecturer, Department of Family and Community Medicine and Department of Medical Imaging, University of Toronto, Toronto, ON.

CLINICAL TOOLS

Abstract: Prostate cancer is a common cancer in men worldwide, and early detection is key to improved patient outcomes. Diagnosis typically involves a combination of clinical examination, prostate-specific antigen blood testing, and imaging studies. Radiology plays an important role, aiding in treatment planning, confirming the diagnosis by directing biopsy, staging the patient, and following treatment course. Imaging modalities for prostate cancer diagnosis include ultrasound, CT, nuclear medicine, and MRI. While MRI is the most sensitive imaging modality, ultrasound is still the preferred modality for measuring the prostate volume. Prostate-specific membrane antigen PET imaging has shown to have superior sensitivity and specificity compared to conventional imaging modalities in the detection of prostate cancer, especially in the context of low PSA. Clinical pearls include performing ultrasound-guided biopsy under local anesthesia to improve patient comfort, and the use of fusion MRI and ultrasound images to facilitate MRI/TRUS fusion-guided biopsy.
Key Words: Prostate cancer, imaging modalities, ultrasound, MRI, CT, PSMA PET.

Members of the College of Family Physicians of Canada may claim MAINPRO-M2 Credits for this unaccredited educational program.

www.cfpc.ca/Mainpro_M2

You can take quizzes without subscribing; however, your results will not be stored. Subscribers will have access to their quiz results for future reference.

Radiology plays a crucial role in prostate cancer diagnosis, aiding in treatment planning, confirming the diagnosis, and directing biopsy.
Imaging modalities for prostate cancer diagnosis include ultrasound, CT, nuclear medicine, and MRI.
MRI is the most sensitive conventional imaging modality for detecting prostate cancer.
Prostate-specific membrane antigen PET imaging has been shown to have superior sensitivity and specificity compared to conventional imaging modalities in the detection of prostate cancer, especially in context of low PSA.
Ultrasound is still the preferred modality for measuring the prostate volume.
Ultrasound-guided biopsy is a minimally-invasive procedure that involves inserting a needle through the rectum via an ultrasound probe guide and into the prostate gland. It is performed under local anesthesia and patients are discharged the same day after a short period of observation in the radiology department.
MRI and ultrasound images can be fused to facilitate MRI/TRUS fusion-guided biopsy, which improves the accuracy of the biopsy procedure.
The use of antibiotic prophylaxis before ultrasound-guided biopsy decreases the risk of infection to approximately 1 in 100 patients.
To have access to full article that these tools were developed for, please subscribe. The cost to subscribe is $80 USD per year and you will gain full access to all the premium content on www.healthplexus.net, an educational portal, that hosts 1000s of clinical reviews, case studies, educational visual aids and more as well as within the mobile app.
Disclaimer: 
Disclaimer at the end of each page

Nutrition Guidelines for Cancer Prevention: More Than Just Food for Thought

Nutrition Guidelines for Cancer Prevention: More Than Just Food for Thought

Teaser: 


Kristen L. Currie, MA, CCRP, Department of Surgical Oncology, Division of Urology, Princess Margaret Hospital, University Health Network (UHN), Toronto, ON.
Sheri Stillman, RD, Clinical Nutrition, Allied Health, Princess Margaret Hospital, UHN, Toronto, ON.
Susan Haines, RD, Clinical Nutrition, Allied Health, Princess Margaret Hospital, UHN, Toronto, ON.
John Trachtenberg, MD, FRCSC, FACS, Department of Surgical Oncology, Division of Urology, Princess Margaret Hospital, UHN, Toronto, ON.

Older adults represent the highest percentage of new cancer diagnoses each year. This, combined with the increasing age of the population, underscores the importance of identifying methods for risk reduction. The World Cancer Research Fund, together with the American Institute for Cancer Research, has published recommendations for cancer prevention through diet and physical activity. These guidelines should be considered when counselling patients in cancer prevention. In this article, colorectal, breast, and prostate cancers are highlighted, and nutritional recommendations for these cancers are presented.
Key words: nutrition, prevention, colorectal cancer, breast cancer, prostate cancer.

Prevention, Diagnosis, and Management of Prostate Cancer: An Update

Prevention, Diagnosis, and Management of Prostate Cancer: An Update

Teaser: 


S. Gogov, MD, Department of Medicine, University Health Network, Toronto, ON.
Shabbir M.H. Alibhai, MD, MSc, FRCPC, Department of Medicine, University Health Network; Departments of Medicine and Health Policy, Management, and Evaluation, University of Toronto, ON.

Prostate cancer remains the most common malignancy in men. Screening remains controversial due to a lack of evidence from randomized trials that it decreases mortality. Treatment decisions are based on assigning patients to one of three risk groups (low, intermediate, or high) based on stage, tumour grade, and prostate-specific antigen level, and considering remaining patient life expectancy (affected by age and comorbidity). Men with low-risk disease can consider expectant management, surgery, or radiotherapy (either external beam or brachytherapy). In intermediate-risk patients, all options except expectant management are associated with excellent long-term survival. In high-risk patients, combining either radiation or surgery with androgen deprivation has emerged as the best option. There is no role for primary androgen deprivation for most patients.
Key words: prostate cancer, screening, treatment, surgery, radiotherapy.

Prostate Cancer: Principles and Practice

Prostate Cancer: Principles and Practice

Teaser: 

Editors: Kantoff P.W., Carroll P.R., D'Amico A.V.
Lippincott Williams & Wilkins, 2001.

Reviewed by: Shabbir M.H. Alibhai, MD, MSc, FRCP(C), Senior Editor, Geriatrics & Aging.

Prostate cancer has been enjoying significant attention in the media over the past few years. Famous individuals such as Health Minister Allan Rock and General Schwartzkopf have been diagnosed and treated in recent years. Much information has been published, in an increasingly compartmentalised and specialised fashion, on the subject in the past decade. This textbook's purpose is to bring together the data from basic science and clinical disciplines in a comprehensive examination of prostate cancer. I should mention at the outset that I have significant research interests in this field, particularly from the geriatric angle, so my perspective on this book may be a little slanted.

To begin with, this reference is written by a host of distinguished American genitourinary oncologists. With very few exceptions, the list of contributors includes the major researchers in the field. Unfortunately, of approximately 100 authors, only two are not American. Thus, a wealth of international (and Canadian) experience in prostate cancer is ignored, and a primarily American perspective on this disease is presented. While this may not be an issue in some fields, in prostate cancer there are significant international differences in thinking with respect to screening, diagnosis and treatment.

The book is organised into eight sections, covering biology, epidemiology, diagnosis, early prostate cancer treatment (two sections), advanced disease (two sections) and future directions. Chapters are generally organised logically, and text and tables are nicely formatted and easy to read. Some chapters have many tables and figures to help facilitate knowledge transfer, whereas others are monotonous and almost exclusively text-based.

The section on biology has some very useful material on anatomy, cellular and molecular biology, genetics and cancer prevention. The anatomy chapter would have been aided by a few diagrams illustrating the anatomy of the prostate in relation to surrounding structures; pity the authors presumed the readers would not find this information useful.

The section on epidemiology is quite interesting. An excellent review of nutritional factors by a world authority includes pertinent sections on vitamins D and E, lycopenes, soy and selenium. However, there is no mention of the ongoing, large SELECT (selenium and vitamin E) randomised prevention trial sponsored by the National Cancer Institute. Peter Albertsen's chapter on age, comorbidity and prostate cancer is particularly relevant to geriatricians and clinical epidemiology-types, such as myself.

Sections 4 and 5, covering single modality and multimodality treatment of localised disease, will be of particular interest to primary care clinicians. There are some useful chapters discussing the role of surgery, external-beam radiotherapy, brachytherapy and combined therapies. One chapter is dedicated to treatment complications such as incontinence and sexual dysfunction, although neither this chapter nor previous ones adequately discuss the risks of treatment complications by modality and patient characteristics. There is also very little discussion of the prevalence of pre-existing incontinence and erectile dysfunction in older adults. This is unfortunate, because both conditions impact upon treatment selection in practice. Moreover, the discussions around treatment do not, in my mind, distinguish the results achieved in specialised tertiary care centres from the average community setting. I found the material on adjuvant hormonal therapy somewhat sparse, given the number of studies published in this area in recent years. I also found the chapter on quality of life long on the theory of quality of life and how to measure it, and short on the actual quality of life after various treatments and complications. This is unfortunate, given the limited evidence in favour of treatment, particularly in older adults, and the major adverse effects of treatment. This is not adequately highlighted.

Chapters in remaining sections cover other interesting areas, including various complications of prostate cancer (hematologic, orthopedic, neurologic), psychosocial issues and a very comprehensive review of pain and symptom management (something with which many clinicians are not very proficient). From an evidence-based medicine perspective, the offerings vary. Some chapters are very careful to discuss the quality and quantity of evidence, whereas others (particularly the chapters on treatment of localised disease) are more cavalier and present the perspectives of expert clinicians with secondary use of studies to justify their positions. Overall, I was disappointed in the offerings, and there was scant mention of several important completed or ongoing clinical trials of management (e.g., the now-published Scandinavian trial of radical prostatectomy vs. watchful waiting and the ongoing PIVOT trial of surgery vs. watchful waiting).

In summary, this textbook will probably be useful to genitourinary specialists (clinicians and researchers) who want quick overviews of specific topics to inform or facilitate more detailed inquiries. Family physicians and general internists should be able to answer most of their questions equally well with a good urology or oncology textbook or a few good review articles on the subject. A stronger focus on methodology (one very good chapter on clinical trials notwithstanding) and evidence-based recommendations would have been an asset. A chapter on informing and empowering patient decision-making also would have been useful, as would a list of Internet-based resources for clinicians and patients. For the generalist, borrowing a copy from your local medical library and waiting for an improved second edition is probably your best bet.

Management of Hot Flashes in Men with Prostate Cancer

Management of Hot Flashes in Men with Prostate Cancer

Teaser: 

Dr. Neil Baum, MD, Urologist and Clinical Associate Professor of Urology, Tulane Medical School, New Orleans, LA, USA.
Dorothea Torti, Stanford University, CA, USA.

Prostate cancer is the most common cancer in men in North America. One of the treatment options is medical castration using LHRH agonists to reduce the production of testosterone by the Leydig cells in the testes. One of the side effects of this class of agents is hot flashes, which can be very disabling and can affect a man's quality of life. This article will discuss the pathophysiology of hot flashes and the treatment of this common side effect with natural and synthetic female hormones, as well as non-hormonal therapies.
Key words: prostate cancer, hot flashes, LHRH agonists, hormone therapy.

Feedback from Our Readers

Feedback from Our Readers

Teaser: 

Feedback from Our Readers

In the July/August 2002 issue of Geriatrics & Aging (Volume 5, Number 6), the article "Dietary Measures to Prevent Prostate Cancer" (pages 18-20) suggested that dairy foods are strongly linked to prostate cancer, and that the higher the intake of dairy foods, the higher the risk of cancer. Mr. Thomas Anderson, PhD from Summerland, B.C., wrote G&A to point out that only defatted dairy products are known to have this effect (e.g., skim milk and fat-free yogurt), whereas unaltered dairy foods do not, and in fact appear to actually protect against prostate, breast and several other types of cancer. References provided by Mr. Anderson include:

  1. Ip C, Scimeca JA, Thompson HJ. Conjugated linoleic acid: powerful anticarcinogen from animal fat sources. Cancer 1994;74:1050-4.
  2. Jonnalagadda SS, Mustad VA, Yu S, et al. Effects of individual fatty acids on chronic diseases. Nutrition Today 1996;31:90-106.
  3. Knekt P, Jarvinen R, Seppanen R, et al. Intake of dairy products and the risk of breast cancer. British Journal of Cancer 1996;73:687-91.
  4. Veierod MB, Leake P, Thelle DS. Dietary fat intake and risk of prostate cancer: a prospective study of 25,708 Norwegian men. Int J Cancer 1997;73:634-8.
  5. Schuuman AG, Van den Brandt PA, Dorrant E, et al. Animal products, calcium and protein and prostate cancer in the Netherlands Cohort Study. Br J Cancer 1999;80:1107-13.

We thank Mr. Anderson for his feedback and encourage our readers to send their comments.

Geriatrics & Aging, 20 Eglinton Ave. West, Suite 1109, Toronto, ON M4R 1K8 Fax: 416-480-2740 or Email: info@geriatricsandaging.ca.

Aggressive Treatment for Prostate Cancer in the Elderly: When is it Appropriate?

Aggressive Treatment for Prostate Cancer in the Elderly: When is it Appropriate?

Teaser: 

James Brown, MD, Minimally Invasive Urologic Oncology Fellow
Department of Urology, Thomas Jefferson University, Assistant Professor of Urology
Medical College of Georgia, Augusta, GA, USA.

Leonard G. Gomella, MD, Bernard Godwin Associate Professor of Prostate Cancer
Director of Urologic Oncology, Department of Urology, Kimmel Cancer Center,
Thomas Jefferson University, Philadelphia, PA, USA.

Abstract
The treatment options for localized prostate cancer are extensive and highly controversial. Although there is general agreement that symptomatic metastatic disease should be treated by hormonal ablation, there is no consensus on how to treat patients with localized disease. While an argument can be made not to screen any patient for prostate cancer, many organizations, including the American Urological Association, support both screening and the treatment of prostate cancer in men with a life expectancy of greater than 10 years. In the asymptomatic, older man with localized, low-risk disease, characterized by a low Gleason score, low PSA and low clinical stage, observation may be the treatment of choice. However, in the older man with localized prostate cancer and high-risk features such as a high Gleason score, aggressive treatment is warranted since many of these men will progress and ultimately die of prostate cancer.

New PSA-Based Screening Tests for Prostate Cancer

New PSA-Based Screening Tests for Prostate Cancer

Teaser: 

Nariman Malik, BSc

Introduction
Prostate cancer is the most frequently diagnosed cancer in Canadian men,1 and is the second leading cause of death due to cancer among North American men, just after lung cancer.3 In the early nineties, the number of prostate cancer cases diagnosed increased dramatically. By 1995, the incidence had peaked and has since leveled off in both Canada and the United States. In 1999, it was estimated that there would be approximately 16,600 new cases of prostate cancer in Canada.2 This increase can be at least partially attributed to newer methods for detecting the disease earlier, particularly since the introduction of routine serum prostate specific antigen (PSA) testing in the early 1990s.1

The risk of developing prostate cancer increases with age. Sixty to seventy-five percent of cancers are diagnosed in men who are over 65 years of age.3 Because of Canada's aging population, primary care physicians will see an increasing number of prostate cancer cases in their practices. It is, therefore, of utmost importance that physicians dealing with the elderly have a clear understanding of the various aspects of this disease. This article focuses on these various aspects of prostate cancer: risk factors, screening techniques, diagnosis and treatment modalities.